DE3717370A1 - Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus - Google Patents
Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitusInfo
- Publication number
- DE3717370A1 DE3717370A1 DE19873717370 DE3717370A DE3717370A1 DE 3717370 A1 DE3717370 A1 DE 3717370A1 DE 19873717370 DE19873717370 DE 19873717370 DE 3717370 A DE3717370 A DE 3717370A DE 3717370 A1 DE3717370 A1 DE 3717370A1
- Authority
- DE
- Germany
- Prior art keywords
- insulin
- mixed crystals
- des
- human
- physiologically compatible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 239000013078 crystal Substances 0.000 title claims abstract description 53
- 102000004877 Insulin Human genes 0.000 title claims abstract description 43
- 229940125396 insulin Drugs 0.000 title claims abstract description 43
- 108090001061 Insulin Proteins 0.000 title claims abstract description 42
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 7
- 239000008177 pharmaceutical agent Substances 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title description 3
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims abstract description 25
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims abstract description 24
- 238000002425 crystallisation Methods 0.000 claims abstract description 8
- 230000008025 crystallization Effects 0.000 claims abstract description 8
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 7
- 108700007397 Arg(B31)- insulin Proteins 0.000 claims abstract description 6
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000007951 isotonicity adjuster Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 235000015277 pork Nutrition 0.000 abstract description 6
- 235000015278 beef Nutrition 0.000 abstract description 5
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000011701 zinc Substances 0.000 description 11
- 229910052725 zinc Inorganic materials 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000004026 insulin derivative Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102000007327 Protamines Human genes 0.000 description 5
- 108010007568 Protamines Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229940048914 protamine Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 101001011741 Bos taurus Insulin Proteins 0.000 description 3
- 101000993800 Sus scrofa Insulin Proteins 0.000 description 3
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 108700025974 depot- insulin Proteins 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- -1 aromatic hydroxy compounds Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000011549 crystallization solution Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- 241001202975 Isophanes Species 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229940119528 pork insulin Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873717370 DE3717370A1 (de) | 1987-05-22 | 1987-05-22 | Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus |
| DE8888107667T DE3867903D1 (de) | 1987-05-22 | 1988-05-13 | Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle und diese mischkristalle enthaltende pharmazeutische mittel. |
| AT88107667T ATE71842T1 (de) | 1987-05-22 | 1988-05-13 | Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle und diese mischkristalle enthaltende pharmazeutische mittel. |
| ES198888107667T ES2032896T3 (es) | 1987-05-22 | 1988-05-13 | Procedimiento para la preparacion de cristales mixtos a base de insulina y derivados de insulina. |
| EP88107667A EP0291863B1 (de) | 1987-05-22 | 1988-05-13 | Mischkristalle aus Insulin und Insulinderivaten, Verfahren zur Herstellung dieser Mischkristalle und diese Mischkristalle enthaltende pharmazeutische Mittel |
| FI882354A FI93797C (fi) | 1987-05-22 | 1988-05-19 | Menetelmä ihmisinsuliinista ja sen johdannaisista koostuvien sekakiteiden valmistamiseksi |
| PT87523A PT87523B (pt) | 1987-05-22 | 1988-05-19 | Processo para a preparacao de cristais mistos de insulina e derivados da insulina, e de composicoes farmaceuticas que os contem |
| NZ224715A NZ224715A (en) | 1987-05-22 | 1988-05-20 | Mixed crystals of insulin and insulin derivatives, pharmaceutical compositions and methods of preparation |
| AU16487/88A AU601280B2 (en) | 1987-05-22 | 1988-05-20 | Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals, and the use thereof for the treatment of diabetes mellitus |
| IL86452A IL86452A (en) | 1987-05-22 | 1988-05-20 | Mixed crystals of insulin and insulin derivatives, a process for their preparation and pharmaceutical agents containing them |
| HU882597A HU203840B (en) | 1987-05-22 | 1988-05-20 | Process for producing mixed cristals suspension and mixed cristals containing native insuline and basically modificated insuline and injectable composition contining them |
| JP63122211A JPS63303930A (ja) | 1987-05-22 | 1988-05-20 | インシユリンおよびインシユリン誘導体の混合結晶 |
| KR1019880005946A KR880013572A (ko) | 1987-05-22 | 1988-05-20 | 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도 |
| ZA883599A ZA883599B (en) | 1987-05-22 | 1988-05-20 | Mixed crystals of insulin and insulin derivatives,a process for the preparation of these mixed crystals,pharmaceutical agents containing these mixed crystals,and the use thereof for the treatment of diabetes mellitus |
| DK278088A DK278088A (da) | 1987-05-22 | 1988-05-20 | Insulinblandindgsktystaller, deres fremstilling og anvendelse |
| US07/196,530 US5028587A (en) | 1987-05-22 | 1988-05-20 | Mixed crystals of insulin and insulin derivatives |
| CA000567377A CA1335924C (en) | 1987-05-22 | 1988-05-20 | Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals, and the use thereof for the treatment of diabetes mellitus |
| PH36954A PH25587A (en) | 1987-05-22 | 1988-05-20 | Mixed crystals of insulin, insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals,, theu use thereof for the treatment of diabetes mellitus |
| NO882207A NO175641C (no) | 1987-05-22 | 1988-05-20 | Fremgangsmåte for fremstilling av blandingskrystaller av insulin og insulinderivater |
| IE152288A IE60649B1 (en) | 1987-05-22 | 1988-05-20 | Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, and pharmaceutical agents containing these mixed crystals |
| GR920400389T GR3004344T3 (enExample) | 1987-05-22 | 1992-04-15 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873717370 DE3717370A1 (de) | 1987-05-22 | 1987-05-22 | Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3717370A1 true DE3717370A1 (de) | 1988-12-01 |
Family
ID=6328227
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19873717370 Withdrawn DE3717370A1 (de) | 1987-05-22 | 1987-05-22 | Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus |
| DE8888107667T Expired - Fee Related DE3867903D1 (de) | 1987-05-22 | 1988-05-13 | Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle und diese mischkristalle enthaltende pharmazeutische mittel. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8888107667T Expired - Fee Related DE3867903D1 (de) | 1987-05-22 | 1988-05-13 | Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle und diese mischkristalle enthaltende pharmazeutische mittel. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5028587A (enExample) |
| EP (1) | EP0291863B1 (enExample) |
| JP (1) | JPS63303930A (enExample) |
| KR (1) | KR880013572A (enExample) |
| AT (1) | ATE71842T1 (enExample) |
| AU (1) | AU601280B2 (enExample) |
| CA (1) | CA1335924C (enExample) |
| DE (2) | DE3717370A1 (enExample) |
| DK (1) | DK278088A (enExample) |
| ES (1) | ES2032896T3 (enExample) |
| FI (1) | FI93797C (enExample) |
| GR (1) | GR3004344T3 (enExample) |
| HU (1) | HU203840B (enExample) |
| IE (1) | IE60649B1 (enExample) |
| IL (1) | IL86452A (enExample) |
| NO (1) | NO175641C (enExample) |
| NZ (1) | NZ224715A (enExample) |
| PH (1) | PH25587A (enExample) |
| PT (1) | PT87523B (enExample) |
| ZA (1) | ZA883599B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19903125A1 (de) * | 1999-01-27 | 2000-08-10 | Aventis Pharma Gmbh | Verfahren zur Trocknung von Proteinkristallen |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK134189D0 (da) * | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
| WO1992010284A2 (en) | 1990-12-07 | 1992-06-25 | Cnc Development, Inc. | Catalytic chemical reactor |
| ES2108122T3 (es) * | 1991-05-24 | 1997-12-16 | Amylin Pharmaceuticals Inc | Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas. |
| DK72793D0 (da) * | 1993-06-21 | 1993-06-21 | Novo Nordisk As | Nyt produkt |
| US5474978A (en) * | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5504188A (en) * | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
| US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US5547929A (en) * | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
| US5597893A (en) * | 1994-10-31 | 1997-01-28 | Eli Lilly And Company | Preparation of stable insulin analog crystals |
| US6004549A (en) * | 1994-12-14 | 1999-12-21 | Schering Corporation | Crystalline protein controlled release compositions |
| CO4970787A1 (es) * | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| CN1125081C (zh) * | 1999-09-08 | 2003-10-22 | 中国科学院上海生物化学研究所 | 重组天然和新型人胰岛素及其制备方法 |
| DE60217066T4 (de) * | 2001-02-09 | 2010-07-01 | Genentech, Inc., South San Francisco | Kristallisierung von igf-1 |
| US7396936B1 (en) | 2004-11-09 | 2008-07-08 | Kemia, Inc. | Modulators of calcitonin and amylin receptor activity |
| WO2008066899A2 (en) * | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Nanoparticulate formulations and methods for the making and use thereof |
| WO2015084694A2 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Method for preparing crystalline insulin |
| US10124040B2 (en) | 2014-08-26 | 2018-11-13 | Merck Sharp & Dohme Corp. | Method for preparing crystalline insulin or insulin analog compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2538018A (en) * | 1944-04-04 | 1951-01-16 | Nordisk Insulinlab | Crystalline product of insulin and alkaline protein and process of making it |
| EG12098A (en) * | 1974-04-13 | 1980-12-31 | Hoechst Ag | New pharmaceutical insulin preparations having antidiabetic activity and process for their manufacture |
| DE3326472A1 (de) * | 1983-07-22 | 1985-02-14 | Hoechst Ag, 6230 Frankfurt | Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus |
| DE3326473A1 (de) * | 1983-07-22 | 1985-01-31 | Hoechst Ag, 6230 Frankfurt | Pharmazeutisches mittel zur behandlung des diabetes mellitus |
| DE3333640A1 (de) * | 1983-09-17 | 1985-04-25 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung |
-
1987
- 1987-05-22 DE DE19873717370 patent/DE3717370A1/de not_active Withdrawn
-
1988
- 1988-05-13 EP EP88107667A patent/EP0291863B1/de not_active Expired - Lifetime
- 1988-05-13 DE DE8888107667T patent/DE3867903D1/de not_active Expired - Fee Related
- 1988-05-13 ES ES198888107667T patent/ES2032896T3/es not_active Expired - Lifetime
- 1988-05-13 AT AT88107667T patent/ATE71842T1/de not_active IP Right Cessation
- 1988-05-19 PT PT87523A patent/PT87523B/pt not_active IP Right Cessation
- 1988-05-19 FI FI882354A patent/FI93797C/fi not_active IP Right Cessation
- 1988-05-20 HU HU882597A patent/HU203840B/hu not_active IP Right Cessation
- 1988-05-20 IL IL86452A patent/IL86452A/xx unknown
- 1988-05-20 DK DK278088A patent/DK278088A/da not_active Application Discontinuation
- 1988-05-20 CA CA000567377A patent/CA1335924C/en not_active Expired - Fee Related
- 1988-05-20 NO NO882207A patent/NO175641C/no unknown
- 1988-05-20 US US07/196,530 patent/US5028587A/en not_active Expired - Fee Related
- 1988-05-20 NZ NZ224715A patent/NZ224715A/en unknown
- 1988-05-20 JP JP63122211A patent/JPS63303930A/ja active Pending
- 1988-05-20 IE IE152288A patent/IE60649B1/en not_active IP Right Cessation
- 1988-05-20 ZA ZA883599A patent/ZA883599B/xx unknown
- 1988-05-20 KR KR1019880005946A patent/KR880013572A/ko not_active Ceased
- 1988-05-20 AU AU16487/88A patent/AU601280B2/en not_active Ceased
- 1988-05-20 PH PH36954A patent/PH25587A/en unknown
-
1992
- 1992-04-15 GR GR920400389T patent/GR3004344T3/el unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19903125A1 (de) * | 1999-01-27 | 2000-08-10 | Aventis Pharma Gmbh | Verfahren zur Trocknung von Proteinkristallen |
| DE19903125B4 (de) * | 1999-01-27 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Trocknung von Kristallen von Insulin oder Insulinanaloga |
Also Published As
| Publication number | Publication date |
|---|---|
| CA1335924C (en) | 1995-06-13 |
| PH25587A (en) | 1991-08-08 |
| GR3004344T3 (enExample) | 1993-03-31 |
| NO175641B (enExample) | 1994-08-01 |
| AU601280B2 (en) | 1990-09-06 |
| IE881522L (en) | 1988-11-22 |
| KR880013572A (ko) | 1988-12-21 |
| IE60649B1 (en) | 1994-08-10 |
| EP0291863A3 (en) | 1990-04-04 |
| EP0291863B1 (de) | 1992-01-22 |
| IL86452A0 (en) | 1988-11-15 |
| NO175641C (no) | 1994-11-09 |
| ES2032896T3 (es) | 1993-03-01 |
| ATE71842T1 (de) | 1992-02-15 |
| HU203840B (en) | 1991-10-28 |
| NO882207D0 (no) | 1988-05-20 |
| DK278088D0 (da) | 1988-05-20 |
| FI882354L (fi) | 1988-11-23 |
| FI93797C (fi) | 1995-06-12 |
| IL86452A (en) | 1993-02-21 |
| ZA883599B (en) | 1989-01-25 |
| PT87523B (pt) | 1992-09-30 |
| DE3867903D1 (de) | 1992-03-05 |
| NZ224715A (en) | 1990-04-26 |
| DK278088A (da) | 1988-11-23 |
| JPS63303930A (ja) | 1988-12-12 |
| EP0291863A2 (de) | 1988-11-23 |
| PT87523A (pt) | 1989-05-31 |
| FI882354A0 (fi) | 1988-05-19 |
| NO882207L (no) | 1988-11-23 |
| AU1648788A (en) | 1988-11-24 |
| HUT46546A (en) | 1988-11-28 |
| FI93797B (fi) | 1995-02-28 |
| US5028587A (en) | 1991-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0291863B1 (de) | Mischkristalle aus Insulin und Insulinderivaten, Verfahren zur Herstellung dieser Mischkristalle und diese Mischkristalle enthaltende pharmazeutische Mittel | |
| DE3880346T2 (de) | Insulinderivate. | |
| AT408611B (de) | Insulinanalogon-protamin-komplex | |
| EP0357978B1 (de) | Pharmazeutische Zubereitung zur Behandlung des Diabetes mellitus | |
| DE69737995T2 (de) | INSULINPREPARATION MIT MAnnitol | |
| DE69409969T2 (de) | Salze der mehrfach ungesättigten fettsäuren und diese enthaltende pharmazeutischen zusammensetzungen | |
| EP0132769B1 (de) | Pharmazeutisches Mittel zur Behandlung des Diabetes mellitus | |
| DE3837825A1 (de) | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung | |
| DE69827357T2 (de) | Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung | |
| DE2415101A1 (de) | Pharmazeutische zusammensetzungen | |
| WO2011003822A2 (de) | Insulinzubereitungen enthaltend methionin | |
| DE2600971A1 (de) | Therapeutisches insulinpraeparat sowie verfahren zur herstellung eines stabilen insulinpraeparats mit dauerwirkung. | |
| CH641046A5 (de) | Verfahren zur herstellung bestaendiger urokinasemittel. | |
| DE2219635A1 (de) | Insulinprodukt | |
| DE2323187C2 (de) | Verfahren zur Herstellung einer stabilisierten, pulverförmigen Secretinzubereitung | |
| CH650678A5 (de) | Pharmazeutisches mittel aus human-insulin und human-proinsulin. | |
| DE2353797A1 (de) | Stabilisierung von prostaglandinen | |
| DE1212679B (de) | Verfahren zur Herstellung von Insulinloesungen | |
| AT401469B (de) | Pharmazeutische wässrige lösung zur parenteralen anwendung enthaltend einen in situ gebildeten komplex von einem alkaloid mit bis-indol-gerüst, sowie verfahren zu deren herstellung | |
| DE69231263T2 (de) | Calcitonin enthaltende pharmazeutische Zusammensetzungen | |
| DE1940130A1 (de) | Injizierbare Insulinaufbereitungen fuer klinische Zwecke und Verfahren zu ihrer Herstellung | |
| DE1802386C2 (de) | Verfahren zur Gewinnung von cytobiotischen Globulinen | |
| DE3875845T2 (de) | Neues hypoglykaemisches und wachstum anregendes mittel. | |
| DE977478C (de) | Verfahren zur Herstellung injizierbarer Insulinpraeparate mit verzoegerter Wirkung | |
| EP0792648A2 (de) | Pharmazeutische Zusammensetzung enthaltend Hirudin und Verfahren zu deren Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8130 | Withdrawal |